Phosphatidylinositol 3-kinase inhibitors, Wortmannin or LY294002, inhibited accumulation of p21 protein after γ-irradiation by stabilization of the protein

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1496, Issue 2-3, 2000, Pages 207-220

  Fukuchi, Kunihiko ^a   Watanabe, Hiroyuki ^a   Tomoyasu, Shigeru ^a   Ichimura, Sachiko ^b   Tatsumi, Kouichi ^b   Gomi, Kunihide ^a  

^a SHOWA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

Ataxia telangiectasia mutated; DNA damage; DNA dependent protein kinase; p21; Wortmannin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; DNA DEPENDENT PROTEIN KINASE; GENE PRODUCT; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN P21; WORTMANNIN;

ANIMAL CELL; ARTICLE; ATAXIA TELANGIECTASIA; BIOACCUMULATION; CELL STRAIN 3T3; CONTROLLED STUDY; DNA DAMAGE; GAMMA RADIATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STABILITY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; 3T3 CELLS; ANDROSTADIENES; ANIMALS; CELL CYCLE PROTEINS; CHROMONES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA DAMAGE; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENZYME INHIBITORS; GAMMA RAYS; GENE EXPRESSION REGULATION; GENE TARGETING; HUMANS; MICE; MORPHOLINES; PROTEIN-SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

ATAXIA; ATAXIA TELANGIECTASIA;

EID: 0034678730     PISSN: 01674889     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4889(00)00018-5     Document Type: Article

References (37)

1. Sherr C.J. G1 phase progression: cycling on cue. Cell. 79:1994;551-555.
2. Morgan D.O. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell Dev. Biol. 13:1997;261-291.
3. Hunter T., Pines J. Cyclins and cancer. II. Cyclin D and CDK inhibitors come of age. Cell. 79:1994;573-582.
4. Glotzer M., Murray A.W., Kirschner M.W. Cyclin is degraded by the ubiquitin pathway. Nature. 349:1991;132-138.
5. Sherr C.J., Roberts J.M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9:1995;1149-1163.
6. Pagano M., Tam S.W., Theodoras A.M., Beer-Romero P., Del Sal G., Chau V., Yew P.R., Draetta G.F., Rolfe M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science. 269:1995;682-685.
7. Koepp D.M., Harper J.W., Elledge S.J. How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell. 97:1999;431-434.
8. Anderson C.W. DNA damage and the DNA-activated protein kinase. Trends Biochem. Sci. 18:1993;433-437.
9. Lavin M.F., Shiloh Y. The genetic defect in ataxia-telangiectasia. Annu. Rev. Immunol. 15:1997;177-202.
10. Shieh S.Y., Ikeda M., Taya Y., Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 91:1997;325-334.
11. Lees-Miller S.P., Sakaguchi K., Ullrich S.J., Appella E., Anderson C.W. Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Mol. Cell. Biol. 12:1992;5041-5049.
12. Canman C.E., Lim D.S., Cimprich K.A., Taya Y., Tamai K., Sakaguchi K., Appella E., Kastan M.B., Siliciano J.D. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science. 281:1998;1677-1679.
13. Banin S., Moyal L., Shieh S., Taya Y., Anderson C.W., Chessa L., Smorodinsky N.I., Prives C., Reiss Y., Shiloh Y., Ziv Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science. 281:1998;1674-1677.
14. Jimenez G.S., Bryntesson F., Torres-Arzayus M.I., Priestley A., Beeche M., Saito S., Sakaguchi K., Appella E., Jeggo P.A., Taccioli G.E., Wahl G.M., Hubank M. DNA-dependent protein kinase is not required for the p53-dependent response to DNA damage. Nature. 400:1999;81-83.
15. Burma S., Kurimasa A., Xie G., Taya Y., Araki R., Abe M., Crissman H.A., Ouyang H., Li G.C., Chen D.J. DNA-dependent protein kinase-independent activation of p53 in response to DNA damage. J. Biol. Chem. 274:1999;17139-17143.
16. Maki C.G., Huibregtse J.M., Howley P.M. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res. 56:1996;2649-2654.
17. Maki C.G., Howley P.M. Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol. Cell. Biol. 17:1997;355-363.
18. Blagosklonny M.V., Wu G.S., Omura S., el-Deiry W.S. Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem. Biophys. Res. Commun. 227:1996;564-569.
19. Fukuchi K., Tomoyasu S., Nakamaki T., Tsuruoka N., Gomi K. DNA damage induces p21 protein expression by inhibiting ubiquitination in ML-1 cells. Biochim. Biophys. Acta. 1404:1998;405-411.
20. Fukuchi K., Tomoyasu S., Watanabe H., Kaetsu S., Tsuruoka N., Gomi K. Iron deprivation results in an increase in p53 expression. Biol. Chem. Hoppe-Seyler. 376:1995;627-630.
21. Fukuchi K., Tomoyasu S., Watanabe H., Tsuruoka N., Gomi K. G1 accumulation caused by iron deprivation with deferoxamine does not accompany change of pRB status in ML-1 cells. Biochim. Biophys. Acta. 1357:1997;297-305.
22. Itoh M., Hamatani K., Komatsu K., Araki R., Takayama K., Abe M. Human chromosome 8 (p12→q22) complements radiosensitivity in the severe combined immune deficiency (SCID) mouse. Radiat. Res. 134:1993;364-368.
23. Savitsky K., Bar-Shira A., Gilad S., Rotman G., Ziv Y., Vanagaite L., Tagle D.A., Smith S., Uziel T., Sfez S., Ashkenazi M., Pecker I., Frydman M., Harnik R., Patanjali S.R., Simmons A., Clines G.A., Sartiel A., Gatti R.A., Chessa L., Sanal O., Lavin M.F., Jaspers N.G.J., Taylor A.M.R., Arlett C.F., Miki T., Weissman S.M., Lovett M., Collins F.S., Shiloh Y. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 268:1995;1749-1753.
24. Watters D., Khanna K.K., Beamish H., Birrell G., Spring K., Kedar P., Gatei M., Stenzel D., Hobson K., Kozlov S., Zhang N., Farrell A., Ramsay J., Gatti R., Lavin M. Cellular localisation of the ataxia-telangiectasia (ATM) gene product and discrimination between mutated and normal forms. Oncogene. 14:1997;1911-1921.
25. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
26. Hartley K.O., Gell D., Smith G.C., Zhang H., Divecha N., Connelly M.A., Admon A., Lees-Miller S.P., Anderson C.W., Jackson S.P. DNA-dependent protein kinase catalytic subunit: a relative of phosphatidylinositol 3-kinase and the ataxia telangiectasia gene product. Cell. 82:1995;849-856.
27. Fukuchi K., Sudo M., Lee Y.S., Tanaka A., Nonoyama M. Structure of Marek's disease virus DNA: detailed restriction enzyme map. J. Virol. 51:1984;102-109.
28. Watanabe H., Fukuchi K., Takagi Y., Tomoyasu S., Tsuruoka N., Gomi K. Molecular analysis of the Cip1/Waf1 (p21) gene in diverse types of human tumors. Biochim. Biophys. Acta. 1263:1995;275-280.
29. Kastan M.B., Zhan Q., el-Deiry W.S., Carrier F., Jacks T., Walsh W.V., Plunkett B.S., Vogelstein B., Fornace A.J. Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 71:1992;587-597.
30. Khanna K.K., Lavin M.F. Ionizing radiation and UV induction of p53 protein by different pathways in ataxia-telangiectasia cells. Oncogene. 8:1993;3307-3312.
31. Canman C.E., Wolff A.C., Chen C.Y., Fornace A.J. Jr., Kastan M.B. The p53-dependent G1 cell cycle checkpoint pathway and ataxia-telangiectasia. Cancer Res. 54:1994;5054-5058.
32. Khanna K.K., Beamish H., Yan J., Hobson K., Williams R., Dunn I., Lavin M.F. Nature of G1/S cell cycle checkpoint defect in ataxia-telangiectasia. Oncogene. 11:1995;609-618.
33. Szekely L., Selivanova G., Magnusson K.P., Klein G., Wiman K.G. EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc. Natl. Acad. Sci. USA. 90:1993;5455-5459.
34. Zhang Q., Gutsch D., Kenney S. Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency. Mol. Cell. Biol. 14:1994;1929-1938.
35. Fritz G., Kaina B. Activation of c-Jun N-terminal kinase 1 by UV irradiation is inhibited by wortmannin without affecting c-jun expression. Mol. Cell. Biol. 19:1999;1768-1774.
36. Nakanishi S., Kakita S., Takahashi I., Kawahara K., Tsukuda E., Sano T., Yamada K., Yoshida M., Kase H., Matsuda Y., et al. Wortmannin, a microbial product inhibitor of myosin light chain kinase. J. Biol. Chem. 267:1992;2157-2163.
37. Cross M.J., Stewart A., Hodgkin M.N., Kerr D.J., Wakelam M.J. Wortmannin and its structural analogue demethoxyviridin inhibit stimulated phospholipase A2 activity in Swiss 3T3 cells. Wortmannin is not a specific inhibitor of phosphatidylinositol 3-kinase. J. Biol. Chem. 270:1995;25352-25355.